🚨🔥@OncoAlert 最新发布。
刚刚由 @sands_jacob 在 @myESMO #ESMO26 上公布了期待已久的 #PracticeChanging 结果：
⭐️ #DeLLphi305 三期试验：
❇️一线维持治疗 #Tarlatamab + #Durvalumab) 对比 #Durvalumab 单药，用于在以 #Chemo + Durvalumab 进行初始诱导 Tx 后的 #ExtensiveStage #SmallCell #LungCancer 患者。
研究显示：
‼️#Impressive 具有统计学显著性且具有临床意义的 ⬆️#OverallSurvival 获益。
✅#mOS: 21.1 vs 12.7 个月 (HR 0.42)
✅12个月 OS: 79.4% vs 53.3%
✅#mPFS: 7.4 vs 1.9 个月 (HR 0.34)
✅#ORR: 26.4 % vs 4.1%
✅ 安全性数据：
⚠️ ≥3级 #AEs: 46.8% vs 40.6%
* Tarlatamab 组：
#CRS: 49.6% (≥3级: 0.4%)
#ICANS: 1.1% (≥3级: 0%)
98 浏览 · 5 赞 · 4 转发 · 0 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%) 👇🏻 https://www.nejm.org/doi/full/10.1056/NEJMoa2609482?query=featured_home在 X 查看被引用的帖子
来源：Rami Manochakian MD, FASCO · x.com